Nature Cell Biology Клеточная биология

Positional replication fork instability drives PARP inhibitor cytotoxicity

Gupta, Dipika, Ding, Xia, Zhang, Lianglin, Coleman, Kate E., Tang, Grace, Lee, Wei Ting C., Oyer, Jon, Kang, Xiaolin, Ramms, Dana J., Yu, Ziqi, VanArsdale, Todd, Fenyo, David, Huang, Tony T., Rothenberg, Eli
Springer Nature · 2026-11-05 · DOI 10.1038/s41556-026-02126-0

Аннотация

Through CRISPR screens and single-molecule imaging, Gupta et al. show that loss of the cohesion acetyltransferase ESCO2 leads to increased G-quadruplex formation at specific regions and drives PARP activation and PARPi hypersensitivity. Although poly(ADP-ribose) polymerase inhibitors (PARPi) show promise for treating homologous recombination-deficient cancers, the observed PARPi hypersensitivity in additional genetic contexts expands their potential use in precision oncology. Yet, the DNA lesions driving PARPi-induced cytotoxicity remain poorly defined. Here we uncover distinct replication-fork lesions in specific genomic regions as key determinants of PARPi cytotoxicity. Using CRISPR screens, we identify that loss of replication-coupled cohesin acetyltransferase ESCO2 confers PARPi hypersensitivity independently of homologous recombination deficiency. Quantitative single-molecule imaging reveals that ESCO2 loss promotes accumulation of G-quadruplex (G4) DNA structures at a subset of replication-associated sites, associated with PARP1 activation and engagement of fork protection factor TIMELESS to mitigate G4-induced stress. Notably, these G4 lesions localize to fragile pericentromeric regions and engage the G4 helicase DDX11. PARP inhibition disrupts this protective G4-processing response by preventing PARP1-dependent engagement of TIMELESS and DDX11, leading to G4 accumulation, DNA damage and chromosomal instability. Together, our findings define the G4–PARP1–TIMELESS–DDX11 axis as a critical safeguard of replication fork stability at hard-to-replicate loci and reveal ESCO2 as a therapeutic target for promoting synthetic lethality in PARPi-treated cancers.

Читать у издателя →